Long-term safety data from the cladribine tablets clinical development program in multiple sclerosis.

MLA

Leist, T., et al. “Long-Term Safety Data from the Cladribine Tablets Clinical Development Program in Multiple Sclerosis.” Multiple Sclerosis and Related Disorders, vol. 46, Nov. 2020, p. 102572. EBSCOhost, https://doi.org/10.1016/j.msard.2020.102572.

APA

Leist, T., Cook, S., Comi, G., Montalban, X., Giovannoni, G., Nolting, A., Damian, D., Syed, S., & Galazka, A. (2020). Long-term safety data from the cladribine tablets clinical development program in multiple sclerosis. Multiple Sclerosis and Related Disorders, 46, 102572. https://doi.org/10.1016/j.msard.2020.102572

Chicago

Leist, T, S Cook, G Comi, X Montalban, G Giovannoni, A Nolting, D Damian, S Syed, and A Galazka. 2020. “Long-Term Safety Data from the Cladribine Tablets Clinical Development Program in Multiple Sclerosis.” Multiple Sclerosis and Related Disorders 46 (November): 102572. doi:10.1016/j.msard.2020.102572.